Treatment with inhibitors of B-cell receptor pathway, CAL-101 and PCI-32765, significantly lowered UGCG expression and sensitized CLL cells to treatment with BCL2 inhibitor ABT-737, increased levels of ceramide and induced apoptosis, further supporting a role for SLs in survival of these cells [264]. The gene discussed is UGCG; the disease is B-cell chronic lymphocytic leukemia.